NICE Doubtful On Cost-Effectiveness Of Tarceva
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.